Introduction
The transglutaminases are a family of at least 9 homologous enzymes that catalyze the cross-linking of proteins by forming ( ␥ -glutamyl)lysine isopeptide bonds, thereby providing stability to a variety of tissues against chemical, mechanical and proteolytic degradation [1] . Both the plasma transglutaminase (FXIIIa) and the tissue enzyme (TG2) have important roles in cardiovascular pathophysiology [2] . In the vasculature, arteriolar structure and function are regulated by the transglutaminases. Increased transglutaminase activity induces vasoconstriction and leads to inward remodeling, while inhibiting transglutaminase activity prevents remodeling and induces vasodilation [3] [4] [5] .
Both TG2 and FXIIIa antigen are also present in larger arteries, especially in those with atherosclerotic plaque [6, 7] . It has been proposed that transglutaminase activity contributes to plaque progression, but also promotes a beneficial effect by preventing plaque rupture [6] . A variety of known substrates for transglutaminase, including collagen types I and II [8] , fibronectin [8] , dermatan sulfate proteoglycan [9] and apolipoprotein (a) [10] are present in the extracellular matrix of the atherosclerotic plaque. However, the endogenous substrates that are responsible for the structural and functional effects of the transglutaminases in arteries and arterioles have not been elucidated. In this study, we demonstrate that vimentin is an endogenous transglutaminase substrate in carotid atherosclerotic plaque, and propose that the modification of vimentin by transglutaminases may regulate vascular structure and reactivity.
Materials and Methods
CHAPS, ␤ -mercaptoethanol, dithiothreitol, extravidin-peroxidase conjugate, anti-vimentin and peroxidase-conjugated anti-goat IgG were all purchased from Sigma (St. Louis, Mo., USA). Amine donor substrate 5-biotinamidopentylamine, Supersignal chemiluminescent substrate, monomeric avidin kit and BCA protein quantification kit were obtained from Pierce (Rockford, Ill., USA). Reagents for electrophoresis and blotting were from Bio-Rad Laboratories (Hercules, Calif., USA). Carotid plaques were harvested by carotid endarterectomy at the North Carolina Baptist Hospital. The acquisition of tissue was approved by the Institutional Review Board of the Wake Forest University School of Medicine.
Labeling of Carotid Artery Transglutaminase Substrates
Carotid artery plaques were used to determine the major substrates for endogenous tissue transglutaminase within atherosclerotic arteries. The carotid endarterectomy plaque ( ϳ 5 g) was obtained immediately from the operating room, rinsed extensively in cold saline containing 10 m M DTT to remove blood, then transported to the lab in ice-cold 100 m M Tris, pH 8. were added. The 0.5-ml aliquot was treated identically, except that 10 m M EDTA was added instead of 10 m M CaCl 2 . The 2 aliquots were incubated for 2 h at 37 ° C. In order to verify that transglutaminase-dependent biotinylation of plaque proteins had occurred, 20-g samples from each aliquot were loaded onto a 10% SDS-PAGE gel under reducing conditions, which was then transferred to nitrocellulose, blocked, incubated with streptavidin-peroxidase and developed with Supersignal chemiluminescent substrate.
The larger aliquot, containing the biotinylated proteins, was dialyzed extensively against TBS, then PBS, to remove free 5-biotinamidopentylamine. The dialysate was then applied to a monomeric avidin affinity column that had been previously treated as recommended by the manufacturer to block all nonreversible binding sites. Unbound material was then removed by extensively washing the column with PBS (10 column volumes in 2.0-ml fractions), with monitoring of the OD 280 until it had reached baseline.
The bound, biotinylated proteins were eluted with 2.0-ml fractions of 2 m M D-biotin in PBS, until background absorbance was achieved. Fractions with OD 280 greater than baseline were pooled, dialyzed against H 2 O, then lyophilized. The lyophilized material was resuspended in 100 l of TBS and an equal volume of 2 ! SDS-PAGE sample buffer (containing ␤ -mercaptoethanol) was added, the samples were boiled for 3 min, then separated by 10% SDS-PAGE. The gel was electroblotted onto PVDF membrane and 3 major bands were excised and subjected to sequencing by automated Edman degradation. A small sample (7 l) was also separated by SDS-PAGE, blotted, blocked, incubated with streptavidin-peroxidase and developed with chemiluminescence.
N-Terminal Sequencing
Amino acid sequence analyses were conducted in the Protein Analysis Core Laboratory of the Comprehensive Cancer Center of Wake Forest University. Samples were analyzed using a PE Biosystems model 492 protein sequencer. Amino acid sequences were searched against the SwissProt and PIR protein sequence databases using FASTA implemented by the Wisconsin Sequence Analysis Package provided by the Genetics Computer Group Inc. (Madison, Wisc., USA).
Immunoblotting of Carotid Plaque Lysates for Vimentin
Carotid endarterectomy tissue homogenates were prepared as described above. Protein concentrations of the extracts were determined using the BCA protein assay kit. Samples were resolved on 10% SDS-PAGE gels under reducing conditions and transferred to nitrocellulose. Blots were blocked in 5% nonfat dry milk in TBST (20 m M Tris-HCl, pH 7.4, 137 m M NaCI, 0.1% Tween 20) and incubated with anti-vimentin (Sigma V4630). The blots were washed and incubated with horseradish peroxidase-conjugated anti-goat IgG, then developed with Supersignal chemiluminescent substrate.
Results
The biotinylation of plaque proteins by endogenous transglutaminase was calcium sensitive ( fig. 1 ) , consistent with the known calcium dependence of transglutaminase activity. The proteins that were biotinylated by endogenous plaque transglutaminase in the presence of CaCl 2 ( fig. 1 , lane 1) were successfully eluted from the monomeric avidin affinity column ( fig. 2 ) . The eluted proteins were lyophilized and separated on a gel to demonstrate that the biotinylated transglutaminase substrates had been recovered ( fig. 3 ) . Proteins of approximately 140, 120, 90, 80, 65, 60, 50, 42, and 20 kDa were purified and blotted to PVDF membrane ( fig. 3 ) . The major band of 42 kDa, along with 2 additional bands of 80 and 65 kDa, was excised from the membrane and sequenced. In each case, the sequence obtained by automated Edman degradation is shown on top (in bold) and the known protein sequence obtained from the literature is diagrammed below ( table 1 ) .
The sequenced 11 residues of protein 1 closely match the N-terminal sequence of transferrin [11] . The se- figure 1 were applied to a monomeric avidin affinity column that had all irreversible biotinbinding sites blocked. Unbound material was washed off with PBS until the OD 280 was at background, then bound material was eluted with 2.0-ml fractions of 2 m M D-biotin in PBS, again until background OD 280 was attained. The eluted fractions were pooled, dialyzed against H 2 O, lyophilized and further analyzed to confirm biotinylation and to sequence prominent bands. quenced 20 residues of protein 2 matched exactly with the N-terminus of human albumin [12] .
Protein 3 at ϳ 42 kDa represents an internal fragment of the intermediate filament protein vimentin. As shown in table 1 , 20 cycles of protein 3 were sequenced with the results shown in bold with the reported sequences presented below [13] . There is a nearly identical match starting at serine residue 72.
We examined carotid endarterectomy plaque tissue to determine whether vimentin could be detected in highmolecular-weight forms. Under reducing conditions, a 120-kDa band was detected with anti-vimentin in all 5 samples, as well as the 60-kDa monomer and apparent proteolytic fragments ( fig. 4 ) . In one sample ( fig. 4 , lane 5), the apparent vimentin dimer was the predominant antigen.
Discussion
In this paper, we have used 5-biotinamidopentylamine to identify several substrates of endogenous carotid artery atherosclerotic plaque tissue transglutaminase. Although many potential substrates have been identified [8] [9] [10] , primarily by using purified extracellular matrix proteins, this study represents the first attempt to label substrates in homogenates of human atherosclerotic plaque. A similar strategy has been successfully employed to identify novel substrates of transglutaminase in the liver [14] and in HT29 colon carcinoma cells [15] .
The major endogenous substrate was an internal fragment of vimentin. The intact protein was also a substrate, since dimers of 120 kDa, consistent with 2 full-length vimentin molecules, were found in arterial lysates. Vimentin is a class III intermediate filament protein primarily expressed in cells of mesenchymal origin, including endothelial cells and smooth muscle cells [16] . Purified vimentin and vimentin within the lens have previously been described as TG2 substrates [17] [18] [19] , with the formation of cross-linked dimers being proposed to play a role in the development of cataracts [17] [18] [19] . Human lens epithelial cells exposed to oxidative stress form vimentin dimers in Table 1 . Protein sequences
Sequences obtained by automated Edman degradation are shown on top (in bold) and the published protein sequences are diagrammed below. The arrow indicates the site of cleavage of vimentin that produces the neoamino terminus revealed by sequencing protein 3. Homogenates of 5 human carotid endarterectomy plaques were prepared as described, then 20 g of protein separated under reducing conditions by 10% SDS-PAGE. Immunoblotting using anti-human vimentin resulted in the detection of vimentin monomer at 60 kDa and an even more prominent apparent dimer band at 120 kDa (proteolytic fragments were also observed). In some samples (lanes 2 and 5), there was very little monomer with predominance of dimer.
situ [19] . To our knowledge, our study is the first to show that vimentin is a substrate for transglutaminase in the vessel wall and to demonstrate the presence of crosslinked vimentin dimers in arterial tissue. The cross-linking of vimentin could be facilitated by the intracellular co-localization of transglutaminase and vimentin, as demonstrated in keratinocytes [18] and fibroblasts [20] . TG2 and FXIIIa are also present as extracellular transglutaminases [1] . It is possible that vimentin becomes a transglutaminase substrate when it is released during cellular apoptosis, an event that occurs with a relatively high frequency within the plaque [21, 22] . It is notable in this regard that tissue transglutaminase activity is increased during apoptosis [23, 24] . Evidence for the cellular release of vimentin within the vessel wall has been demonstrated in patients with accelerated transplant vasculopathy. These patients have high levels of anti-endothelial cell antibodies, which are directed at a 56-to 58-kDa antigen [25] , which has been identified as vimentin [26] . We also demonstrated that albumin and transferrin were endogenous transglutaminase substrates. Thung et al. [27] previously reported that transglutaminase could cross-link human serum albumin into multimers (up to hexamers). Transglutaminase is also known to cross-link certain amine-containing drugs (such as isoniazid and hydralazine) to albumin [28] . To our knowledge, transferrin has not previously been described as a transglutaminase substrate. Using purified protein, we have confirmed that transferrin is a substrate for TG2 and FXIIIa (data not shown). However, the significance of albumin and transferrin serving as substrates for transglutaminases is currently unknown.
An important role for vimentin has been demonstrated in arterial physiology. Mice lacking vimentin have impaired arterial vasodilation in response to alterations in blood flow as a result of an imbalance in the levels of endothelin-1 and nitric oxide [29] [30] [31] . These effects may occur because of the critical role that cytoskeletal components play in mediating shear stress-induced release of endothelial-derived vasoactive substances. The absence of vimentin also has important consequences on vascular structure. Vimentin -/-mice have a reduction in inward remodeling in response to reduce blood flow in the carotid, but exhibit increased remodeling in response to elevated blood flow [31] . Inward remodeling, a structural reorganization of a constant amount of vascular tissue with a reduction in luminal diameter, occurs in settings of persistent vasoconstriction or a reduction in shear stress from reduced blood flow [32] . Both TG2 and FXIIIa have been shown to enhance inward remodeling in response to low flow states [3] [4] [5] . Furthermore, TG2 activity is associated with vasoconstrictive responses, perhaps mediated via the activation of the RhoA/ROCK-2 kinase pathway in vascular smooth muscle cells [33] . Since small GTPases including RhoA regulate vimentin and other cytomatrix components [34] , we postulate that TG2-induced alterations of vimentin structure either directly (via cross-linking) or indirectly (via RhoA) regulate vasomotor tone. Furthermore, since both TG2 and vimentin also contribute to inward remodeling, we speculate that transglutaminase-mediated vimentin dimerization could provide a novel unifying pathway by which vasodilatory and remodeling responses are regulated.
